Analysis – Page 201 – Goldea Capital

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

Written by Customer Service on May 21, 2026. Posted in Public Companies.

In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse events Activity of the combined regimen across all dose cohorts achieved 39% ORR and 7.3-month median PFS In the 250 mg QD 5:2 intermittent dose cohort, 50% ORR, 9.2-month median DOR, and low frequency of high-grade adverse events was observed, suggesting a potential optimal dose combinationSAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that data from Part 1 of the Phase 1b MUIR trial will be presented at the 2026 American Society...

VCI Global Received NASDAQ Notice Related to Late Filing of 20-F

Written by Customer Service on May 21, 2026. Posted in Public Companies.

KUALA LUMPUR, Malaysia, May 21, 2026 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”) today announced that it received a notification letter from the Nasdaq Stock Market LLC (“NASDAQ”) on May 19, 2026 regarding the delayed filing of the Company’s Form 20-F for the financial year ended December 31, 2025. The notice relates to the timing of the Company’s filing of its Form 20-F under NASDAQ Listing Rule 5250(c)(1), which requires listed companies to periodically file financial reports with the U.S. Securities and Exchange Commission (“SEC”). As previously disclosed, the Company filed a Form 12b-25 (Notification of Late Filing) with the SEC on May 1, 2026, after requiring additional time to complete the preparation and final review of its financial statements and related disclosures for the 2025...

Canadian Net REIT Announces 2026 First-Quarter Results and a Distribution Increase

Written by Customer Service on May 21, 2026. Posted in Earnings Releases And Operating Results.

REIT also announces monthly distributions for Q3 2026 MONTRÉAL, May 21, 2026 (GLOBE NEWSWIRE) — Canadian Net Real Estate Investment Trust (“Canadian Net” or the “REIT”) (TSX-V: NET.UN) today reported its results for the quarter ended March 31st, 2026 (“Q1 2026”). The REIT also announced an increase in annual distributions and distributions for July, August and September 2026 (“Q3 2026”). “We are pleased to report continued FFO per unit1 growth and to announce a 3% increase in our distribution, a testament to the strength and predictability of our portfolio,” said Kevin Henley, President and CEO. “As expected, FFO per unit1 growth this quarter was impacted by the carrying cost of our recently issued debenture, which was raised precisely to accelerate our acquisition pipeline. This impact is temporary and will reverse...

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors

Written by Customer Service on May 21, 2026. Posted in Public Companies.

Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Combined results evaluating AKY-2519 across several B7-H3 expressing tumor types, including metastatic castration-resistant prostate cancer (mCRPC), suggest a potentially differentiated profile compared to approved radiopharmaceuticals Aktis to hold conference call on Wednesday, May 27, 2026, at 8:00 a.m. ET with leading clinical investigators, Oliver Sartor, M.D., and Timothy Yap, MBBS, Ph.D., to discuss resultsBOSTON, May 21, 2026 (GLOBE NEWSWIRE) — Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today...

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Written by Customer Service on May 21, 2026. Posted in Public Companies.

Cash Runway Extended to Finance the Parkinson’s Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) — Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced the closing of its registered direct offering, pursuant to the securities purchase agreements with certain investors, for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering were approximately $2.0 million (the “Offering”). “Yesterday’s capital raise helps the Company prepare for key milestones anticipated in the next year,” said Christer Rosén, Chairman and CEO of Jupiter...

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

Written by Customer Service on May 21, 2026. Posted in Public Companies.

Preliminary mPFS of 15.2 months; mDOR not reached Robust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastases ORR 60% in patients with a broad spectrum of EGFR-NCMs, including PACC Dose dependent and manageable AE profile, no new safety signals observed Webcast on Thursday, May 21, 2026 at 5:30 pm EDTCAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced positive results from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) non-classical mutations (NCMs). These data will be presented by Julia Rotow, M.D., Clinical Director,...

Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026

Written by Customer Service on May 21, 2026. Posted in Public Companies.

LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois. “Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival compared to marrow-only relapse. With an overall response rate of 59% and a median duration of response (mDOR) of 42.6 months for patients with EMD, obe-cel may be considered as a...

Abcourt announces its financial results for the quarter ended March 31, 2026

Written by Customer Service on May 21, 2026. Posted in Earnings Releases And Operating Results.

ROUYN-NORANDA, Quebec, May 21, 2026 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (“Abcourt” or the “Corporation”) (TSX Venture: ABI) (OTCQB : ABMBF) announces its financial results for the third quarter ended March 31, 2026. All monetary values in this press release are expressed in Canadian dollars, unless otherwise indicated. Financial statements and management discussion and analysis are available on SEDAR+. Summary of financial results(In dollars) Three months ended March 31, Nine months ended March 31, 2026 2025 2026 2025 Revenues 7,877,554 – 12,766,703 – Costs of sales 12,779,778 – 24,457,126 – Tax credit resources (1,032,250 ) – (3,288,901 ) – Loss from mining operations (3,869,974 ) – (8,401,522 ) – Administration expenses 1,469,001 1,068,917 3,646,730 2,499,582 Care...

Banqup delivers 40,3% y/y growth in subscription revenue in Q1 2026

Written by Customer Service on May 21, 2026. Posted in Earnings Releases And Operating Results.

La Hulpe, Belgium – 21 May 2025, 22:30 CEST – REGULATED INFORMATION – Banqup Group SA, (Euronext: BANQ) (Banqup, Company), a leading provider of integrated financial workflow management solutions, publishes its business update for the first quarter of 2026. Key HighlightsSolid Group revenue1,2 growth of 5,0% y/y from € 12,5m in Q1 2025 to € 13,1m in Q1 2026. This was primarily driven by strong growth momentum in digital revenue1 (+14,4% y/y). Banqup’s ARR Digital Services Revenue increased by 12,7% y/y, reaching € 47,0m at the end of March 2026. Completed divestment of Baltic Activities to Fitek Oü on 16 March 2026, aligning with Banqup’s strategy to streamline its operations into a pure-play SaaS company. Including proceeds from the sale, liquidity as of 31 March 2026 stands at € 8,6m. Launched Value Creation Plan to drive cost optimisations...

OFA Group Transitions to U.S. Domestic Issuer Status; Reaffirms United States as the Center of Its Growth Strategy

Written by Customer Service on May 21, 2026. Posted in Public Companies.

Torrance, California, May 21, 2026 (GLOBE NEWSWIRE) — OFA Group (NASDAQ: OFAL) (“OFA Group” or the “Company”) today announced that, effective April 1, 2026, the Company ceased to qualify as a “foreign private issuer” within the meaning of Rule 405 under the Securities Act of 1933 and Rule 3b-4 under the Securities Exchange Act of 1934, and now reports as a U.S. domestic issuer under the Securities and Exchange Commission’s rules applicable to domestic registrants. The transition reflects the Company’s evolution over the past year and the geographic concentration of its shareholders, leadership, operations, and revenue in the United States. While OFA Group remains incorporated in the Cayman Islands and maintains a subsidiary in Hong Kong, the Company’s principal executive offices,...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals